ovarian adnexal mass
Aspira Receives NY State Approval for OvaWatch Test
Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.
Aspira Women's Health Offers $1.9M in Stock Through Private Placement
The company has offered roughly 1.3 million shares of common stock and warrants to purchase an equal number of shares at a combined price of $1.53 per share.
Aspira Announces $5.5M Direct Offering, Concurrent Private Placement
Aspira is selling shares and warrants to an institutional investor, existing shareholders, and CEO Nicole Sandford to raise funds for general corporate purposes.
Aspira Q4 Revenues up 36 Percent
The company reported total revenues of $1.9 million, up from $1.4 million in Q4 2020, while sales of its OVA1plus test were up 23 percent.
Aspira Women's Health Preliminary Q4 OVA1 Sales up 23 Percent; Firm Details Pipeline Progess
The company also announced a five-year deal with healthcare group Axia Women's Health to provide in-house genetic carrier screening.